Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform

/PRNewswire/ -- Degron Therapeutics ("Degron"), a biotechnology company developing a new class of small-molecule medicines that target previously undruggable...

Related Keywords

Shanghai ,China ,Jing Yu ,Shanxi ,Lily Zou ,Yong Cang ,Shanghaitech University , ,Dyee Capital ,Baidu Venture ,Neux Capital ,Yuanbio Venture ,Degron Therapeutics ,Med Fine Capital ,